eCite Digital Repository

Long-acting beta2-agonists in asthma: an overview of Cochrane systematic reviews

Citation

Walters, JAE and Wood-Baker, R and Walters, EH, Long-acting beta2-agonists in asthma: an overview of Cochrane systematic reviews, Respiratory Medicine, 99, (4) pp. 384-395. ISSN 0954-6111 (2005) [Refereed Article]

DOI: doi:10.1016/j.rmed.2005.01.003

Abstract

According to major asthma management guidelines, long-acting β2-agonists (LABAs) should be used only when asthma remains symptomatic in patients already receiving regular inhaled corticosteroids (ICSs). A large Cochrane systematic review provides evidence that LABAs are safe and beneficial in control of asthma; sub-group analyses indicating that this is true when ICSs are used and in their absence. Two other Cochrane systematic reviews have found that LABAs are more effective than regular short-acting β2 -agonists, and are as effective as theophylline with fewer side-effects. These reviews support guidelines in the use of LABA as additional therapy when asthma is inadequately controlled by ICS at moderate dose. However, guidelines may be too conservative, and more studies in stable mild asthma comparing their use and safety with placebo and ICS are required. © 2005 Elsevier Ltd. All rights reserved.

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Cardiorespiratory Medicine and Haematology
Research Field:Respiratory Diseases
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Respiratory System and Diseases (incl. Asthma)
Author:Walters, JAE (Dr Julia Walters)
Author:Wood-Baker, R (Professor Richard Wood-Baker)
Author:Walters, EH (Professor Haydn Walters)
ID Code:37205
Year Published:2005
Web of Science® Times Cited:19
Deposited By:Medicine (Discipline)
Deposited On:2005-08-01
Last Modified:2006-05-10
Downloads:0

Repository Staff Only: item control page